Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis.
An investigation was made on the concentration of levofloxacin (LVFX) in cervical mucus and its clinical effects on cervicitis. The results were as follows: 1) The concentrations of orally administered LVFX in the cervical mucus of 110 subjects were determined by HPLC. During 1-4 hour after the administration the mean concentration of LVFX in the cervical mucus reached a level of 2 micrograms/g, which was higher than the serum level. The transfer of LVFX to the cervical mucus was almost the same as that to other genital organs. 2) When LVFX was given to 102 patients at a dose of 100-200 mg, t.i.d for 4-5 days and the efficacy was evaluated with clinical improvement, the clinical efficacy rate of LVFX was 72/102 (70.6%). Significant bacteriological effects were observed in 70/73 (95.9%), especially, the disappearance rate of C. trachomatis was 18/18 (100%). 3) The administration LVFX did not cause any subjective or objective side effects and any abnormalities were not detected in the laboratory test done in this study. These results demonstrate that LVFX can be sufficiently transferred to the cervical mucus for the treatment of cervicitis due to the infection of C. trachomatis etc.
Chimura
T
T
Department of Obstetrics and Gynecology, Shirataka Hospital.
Arai
M
M
Onuma
Y
Y
Oda
T
T
Kawagoe
S
S
Kunii
K
K
Saito
T
T
Saito
N
N
Sato
F
F
Numazaki
M
M
Matsuo
M
M
Murayama
K
K
Morizaki
N
N
D000328:Adult; D000890:Anti-Infective Agents / Q000032:analysis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002582:Cervix Mucus / Q000737:chemistry*; D002692:Chlamydia trachomatis / Q000187:drug effects; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008875:Middle Aged; D015242:Ofloxacin / Q000032:analysis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002575:Uterine Cervicitis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin